グルココルチコイド受容体経由でのコルチコステロンの増加による肝臓のフラビン含有モノオキシゲナーゼ3の上昇は妊娠糖尿病に寄与する.
PubMedで要約を見る
まとめ
この要約は機械生成です。妊娠中のコルチゾールは,肝臓のフラビン含有モノオキシゲナーゼ3 (FMO3) を活性化させ,妊娠糖尿病 (GDM) の高血糖症を悪化させる. FMO3を3,3'-ディインドルメタンで阻害すると,マウスのグルコース耐性が改善された.
科学分野
- 内分泌学と代謝
- 分子生物学
- 薬理学について
背景
- 妊娠中の糖尿病 (GDM) は妊娠中の合併症と生涯にわたる代謝障害のリスクを高めます.
- コルチゾールの上昇と肝臓のフラビン含有モノオキシゲナーゼ3 (FMO3) はGDMと関連しているが,その相互作用は不明である.
研究 の 目的
- コルチゾールがGDMにおけるFMO3に影響を与えるメカニズムを解明する.
- GDMの病原性におけるコルチゾール-FMO3軸の役割を調査する.
- GDMの治療戦略としてFMO3抑制を評価する.
主な方法
- コルチゾール,グルココルチコイド受容体,肝臓FMO3を含むシグナル伝達経路を調査した.
- トリメチラミンN酸化物 (TMAO) の生成と高血糖症に対するFMO3の影響を評価した.
- GDMのマウスモデルで3,3'-ディインドリルメタンでFMO3の薬理学的抑制を活用した.
主要な成果
- GDMにおけるコルチゾールの上昇はグルココルチコイド受容体を活性化し,肝臓FMO3を上調する.
- 肝臓のTMAO生成を増加させ,Akt- FOXO1- G6PC軸経由で高血糖症を悪化させる.
- 3, 3'- ディインドルメタンによるFMO3阻害は,TMAOを減少させ,Akt- FOXO1- G6PC経路を抑制することで,妊娠マウスのグルコース耐性を改善した.
結論
- GDMにおける肝臓FMO3の新型グルココルチコイド駆動の調節メカニズムを特定した.
- FMO3はGDMにおける高血糖症の主要な媒介体である.
- GDMにおけるグルコースホメオスタシスの改善のための治療薬としての可能性を示しています.
関連する概念動画
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

